Vanillin volume guidance FY27
4,000 MT
+67% YoY
Management expects to double vanillin sales from ~2,400 MT in FY26 to 4,000 MT in FY27.
CAMLINFINESCIENCES
Other
10 Feb 2026
Camlin Fine Sciences Limited — Q3 FY26
Camlin Fine Sciences reported Q3 FY26 revenue of ₹572 crore, up 6% YoY, driven by blends growth (+11% YoY) and the VPI acquisition.
✓ Verified against BSE filing
2-Min Summary
✦ AI-Generated from Full Transcript
Camlin Fine Sciences reported Q3 FY26 revenue of ₹572 crore, up 6% YoY, driven by blends growth (+11% YoY) and the VPI acquisition. EBITDA margin contracted 60 bps YoY to 6.7%, impacted by lower vanillin sales (deliberately deferred to benefit from US tariff reduction) and margin pressure in the straights business (TBHQ/BHA). Management guided for FY27 vanillin volumes of 4,000 metric tons (vs ~2,400 in FY26) and blends growth of 20-25%, targeting overall revenue of ₹2,200 crore. A fire at a Brazil blending unit destroyed ~₹33 crore of inventory and equipment, but insurance coverage is expected. Key risk: delay in US tariff reduction or liquidation of European subsidiary could impact cash flows.
Key Numbers
Blends revenue growth Q3
₹271 crore
+11% YoY
Blends segment grew 11% YoY, driven by organic growth and VPI acquisition (₹13 crore contribution).
Vanillin channel stock
400 MT
N/A
Company holds 400 MT of vanillin inventory in US, partly committed at $12.5/kg, awaiting tariff benefit.
Brazil fire loss
₹33 crore
N/A
Fire destroyed inventory (₹28 crore) and equipment (₹4.5 crore) at a blending unit; insurance survey pending.
Management Guidance
FY27 vanillin volume target of 4,000 MT
Management expects to sell 4,000 metric tons of vanillin in FY27, up from ~2,400 MT in FY26, driven by US tariff reduction and channel stock liquidation.
Management guidance revenueFY27 revenue target of ₹2,200 crore
Company targets ₹2,200 crore revenue in FY27, assuming current pricing and 20-25% blends growth.
Management guidance revenueEBITDA margin improvement to 12-14%
Management guided EBITDA margin to improve to 12-14% in FY27, driven by higher vanillin realizations and blends growth.
Management guidance marginsVPI and Vitafor revenue growth of 40-50% in FY27
VPI (₹12-13 crore/month) and Vitafor (€12-13 million annual) are expected to grow 40-50% in FY27 through market expansion.
Management guidance growthKey Risks
Delay in US tariff reduction
If the US-India trade deal is not signed, vanillin realizations may remain at $12.5/kg instead of improving to $14-15/kg, impacting margins.
high · management_commentaryBrazil fire insurance recovery uncertainty
The fire at the Brazil blending unit caused ₹33 crore loss; insurance survey is pending and recovery timeline is uncertain, potentially impacting Q4 results.
medium · management_commentaryLiquidation of European subsidiary may not proceed as planned
If the court does not approve liquidation by February 26, the cash bleed of ~₹8 crore per quarter from Europe could continue.
medium · analyst_questionIntense competition in straights business
The TBHQ/BHA segment faces pricing pressure from local manufacturers, leading to margin compression and plateaued growth.
medium · management_commentaryNotable Quotes
We would have pushed and sold another 200 tons. We went slow and try to push it in the next quarter so that we get the duty benefit.
Our guidance for FY27 is between the two, the total would be 4,000 metric tons.
The gross margins should improve by at least a couple of percent with higher realization of vanillin as well as growth in the blends business.
Frequently Asked Questions
What was Camlin Fine Sciences's revenue in Q3 FY26?
Camlin Fine Sciences reported revenue of ₹457 Cr in Q3 FY26, representing a +6% change compared to the same quarter last year.
What guidance did Camlin Fine Sciences management give for FY27?
FY27 vanillin volume target of 4,000 MT: Management expects to sell 4,000 metric tons of vanillin in FY27, up from ~2,400 MT in FY26, driven by US tariff reduction and channel stock liquidation. FY27 revenue target of ₹2,200 crore: Company targets ₹2,200 crore revenue in FY27, assuming current pricing and 20-25% blends growth. EBITDA margin improvement to 12-14%: Management guided EBITDA margin to improve to 12-14% in FY27, driven by higher vanillin realizations and blends growth. VPI and Vitafor revenue growth of 40-50% in FY27: VPI (₹12-13 crore/month) and Vitafor (€12-13 million annual) are expected to grow 40-50% in FY27 through market expansion.
What are the key risks for Camlin Fine Sciences in FY27?
Key risks include Delay in US tariff reduction — If the US-India trade deal is not signed, vanillin realizations may remain at $12.5/kg instead of improving to $14-15/kg, impacting margins.; Brazil fire insurance recovery uncertainty — The fire at the Brazil blending unit caused ₹33 crore loss; insurance survey is pending and recovery timeline is uncertain, potentially impacting Q4 results.; Liquidation of European subsidiary may not proceed as planned — If the court does not approve liquidation by February 26, the cash bleed of ~₹8 crore per quarter from Europe could continue.; Intense competition in straights business — The TBHQ/BHA segment faces pricing pressure from local manufacturers, leading to margin compression and plateaued growth..
Did Camlin Fine Sciences meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Camlin Fine Sciences Q3 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary verified against official BSE/NSE filings.